Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer

D. Raghavan, B. Koczwara, M. Javle

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Despite the use of cytotoxic chemotherapy for advanced prostate cancer for half a century, its clinical utility in this setting remains undefined. Based on traditional methods of assessment, the list of the most active cytotoxic agents includes cyclophosphamide, doxorubicin, mitoxantrone and cisplatin. With the introduction of more structured methods of assessment, including careful assessment of indices of quality of life and serial measurement of serum prostate-specific antigen (PSA), the role of cytotoxic agents is being re-assessed. In view of the cell cycle characteristics of prostate cancer, there appears to be an emerging role for combination inhibitors of mitosis, including estramustine in combination with the vinca alkaloids, etoposide or paclitaxel.

Original languageEnglish
Pages (from-to)566-574
Number of pages9
JournalEuropean Journal of Cancer Part A
Volume33
Issue number4
DOIs
Publication statusPublished - 1 Apr 1997
Externally publishedYes

Keywords

  • chemotherapy
  • progress
  • prostate cancer
  • PSA
  • therapy
  • treatment

Fingerprint Dive into the research topics of 'Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer'. Together they form a unique fingerprint.

Cite this